| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Electroconvulsive Therapy | 244 | 2022 | 402 | 56.160 |
Why?
|
| Depressive Disorder, Major | 58 | 2022 | 439 | 12.750 |
Why?
|
| Bipolar Disorder | 40 | 2020 | 307 | 7.890 |
Why?
|
| Depressive Disorder | 67 | 2017 | 621 | 6.430 |
Why?
|
| Depression | 25 | 2021 | 943 | 4.540 |
Why?
|
| Antidepressive Agents | 23 | 2019 | 216 | 4.360 |
Why?
|
| Depressive Disorder, Treatment-Resistant | 11 | 2021 | 29 | 4.230 |
Why?
|
| Electroencephalography | 26 | 2019 | 418 | 3.740 |
Why?
|
| Catatonia | 14 | 2020 | 20 | 3.740 |
Why?
|
| Humans | 280 | 2022 | 68618 | 3.180 |
Why?
|
| Ketamine | 9 | 2022 | 57 | 3.030 |
Why?
|
| Cognition Disorders | 12 | 2022 | 342 | 2.780 |
Why?
|
| Anesthesia | 12 | 2018 | 120 | 2.600 |
Why?
|
| Seizures | 16 | 2019 | 279 | 2.420 |
Why?
|
| Mental Disorders | 10 | 2019 | 659 | 2.410 |
Why?
|
| Schizophrenia | 9 | 2019 | 206 | 2.160 |
Why?
|
| Treatment Outcome | 59 | 2021 | 7029 | 1.890 |
Why?
|
| Psychotic Disorders | 13 | 2016 | 157 | 1.790 |
Why?
|
| Succinylcholine | 7 | 2018 | 15 | 1.780 |
Why?
|
| Anesthetics, Intravenous | 6 | 2016 | 27 | 1.740 |
Why?
|
| Venlafaxine Hydrochloride | 7 | 2021 | 42 | 1.660 |
Why?
|
| Female | 112 | 2020 | 38074 | 1.550 |
Why?
|
| Neuromuscular Depolarizing Agents | 5 | 2018 | 12 | 1.480 |
Why?
|
| Male | 106 | 2020 | 37321 | 1.430 |
Why?
|
| Nortriptyline | 8 | 2015 | 28 | 1.430 |
Why?
|
| Geriatric Psychiatry | 2 | 2019 | 9 | 1.300 |
Why?
|
| Fever | 3 | 2014 | 96 | 1.280 |
Why?
|
| Cognition | 9 | 2022 | 513 | 1.280 |
Why?
|
| Hypnotics and Sedatives | 5 | 2017 | 96 | 1.250 |
Why?
|
| Methohexital | 5 | 2016 | 7 | 1.240 |
Why?
|
| Obsessive-Compulsive Disorder | 7 | 2019 | 88 | 1.230 |
Why?
|
| Drug Resistance | 8 | 2018 | 223 | 1.220 |
Why?
|
| Aged | 61 | 2021 | 14862 | 1.210 |
Why?
|
| Parkinson Disease | 5 | 2015 | 272 | 1.170 |
Why?
|
| Antipsychotic Agents | 8 | 2021 | 247 | 1.170 |
Why?
|
| Anesthesia, Intravenous | 4 | 2014 | 12 | 1.120 |
Why?
|
| Middle Aged | 73 | 2021 | 21147 | 1.100 |
Why?
|
| Anesthesia, General | 7 | 2017 | 86 | 1.070 |
Why?
|
| Anesthesiology | 2 | 2018 | 63 | 1.060 |
Why?
|
| Anesthetics, Dissociative | 3 | 2014 | 11 | 1.040 |
Why?
|
| Electrodes | 11 | 2017 | 147 | 1.020 |
Why?
|
| Deep Brain Stimulation | 2 | 2016 | 71 | 0.990 |
Why?
|
| Depression, Postpartum | 2 | 2017 | 9 | 0.980 |
Why?
|
| Aged, 80 and over | 24 | 2020 | 4848 | 0.940 |
Why?
|
| Excitatory Amino Acid Antagonists | 2 | 2015 | 128 | 0.930 |
Why?
|
| Psychiatric Status Rating Scales | 18 | 2018 | 782 | 0.920 |
Why?
|
| Adult | 74 | 2021 | 21403 | 0.920 |
Why?
|
| Mood Disorders | 9 | 2019 | 132 | 0.920 |
Why?
|
| Combined Modality Therapy | 15 | 2019 | 951 | 0.860 |
Why?
|
| Muscle Relaxation | 5 | 2018 | 31 | 0.830 |
Why?
|
| Lithium | 7 | 2021 | 76 | 0.790 |
Why?
|
| Propofol | 4 | 2016 | 36 | 0.770 |
Why?
|
| Bradycardia | 2 | 2022 | 45 | 0.760 |
Why?
|
| Severity of Illness Index | 14 | 2018 | 1851 | 0.760 |
Why?
|
| Terminology as Topic | 3 | 2019 | 141 | 0.750 |
Why?
|
| Societies, Medical | 4 | 2014 | 403 | 0.730 |
Why?
|
| Mouth Protectors | 1 | 2019 | 2 | 0.700 |
Why?
|
| Suicide, Attempted | 5 | 2020 | 72 | 0.690 |
Why?
|
| Lorazepam | 3 | 2015 | 54 | 0.690 |
Why?
|
| Medical Device Legislation | 1 | 2019 | 1 | 0.680 |
Why?
|
| Dementia | 3 | 2010 | 158 | 0.660 |
Why?
|
| Electrocardiography | 6 | 2020 | 601 | 0.630 |
Why?
|
| Mastocytosis, Systemic | 1 | 2017 | 3 | 0.610 |
Why?
|
| Clinical Protocols | 3 | 2014 | 172 | 0.610 |
Why?
|
| Muscle Relaxants, Central | 3 | 2013 | 13 | 0.610 |
Why?
|
| Clozapine | 2 | 2014 | 46 | 0.600 |
Why?
|
| Secondary Prevention | 7 | 2019 | 291 | 0.590 |
Why?
|
| Functional Laterality | 7 | 2017 | 240 | 0.580 |
Why?
|
| Neuropsychological Tests | 10 | 2019 | 517 | 0.580 |
Why?
|
| Mass Media | 1 | 2017 | 29 | 0.570 |
Why?
|
| Anesthetics | 2 | 2014 | 30 | 0.570 |
Why?
|
| Lithium Compounds | 4 | 2017 | 15 | 0.570 |
Why?
|
| Suicide | 6 | 2021 | 116 | 0.560 |
Why?
|
| Electric Stimulation Therapy | 2 | 2016 | 147 | 0.560 |
Why?
|
| Piperidines | 1 | 2017 | 123 | 0.560 |
Why?
|
| Evidence-Based Medicine | 3 | 2020 | 438 | 0.560 |
Why?
|
| Reflex | 2 | 2022 | 21 | 0.540 |
Why?
|
| United States Food and Drug Administration | 2 | 2019 | 131 | 0.540 |
Why?
|
| Laryngeal Masks | 1 | 2016 | 9 | 0.540 |
Why?
|
| Amnesia | 2 | 2016 | 17 | 0.540 |
Why?
|
| Intracranial Arteriovenous Malformations | 1 | 2016 | 15 | 0.540 |
Why?
|
| Patient Safety | 5 | 2017 | 202 | 0.540 |
Why?
|
| PubMed | 1 | 2015 | 21 | 0.520 |
Why?
|
| Hypohidrosis | 1 | 2015 | 5 | 0.520 |
Why?
|
| Flushing | 1 | 2015 | 7 | 0.520 |
Why?
|
| Erythema | 1 | 2015 | 18 | 0.520 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 2015 | 14 | 0.520 |
Why?
|
| Chewing Gum | 1 | 2015 | 6 | 0.520 |
Why?
|
| Suicidal Ideation | 2 | 2016 | 106 | 0.510 |
Why?
|
| Androstanols | 2 | 2012 | 7 | 0.510 |
Why?
|
| Psychomotor Agitation | 2 | 2013 | 63 | 0.510 |
Why?
|
| Recurrence | 11 | 2019 | 948 | 0.500 |
Why?
|
| Amnesia, Anterograde | 1 | 2015 | 1 | 0.500 |
Why?
|
| Neurosurgical Procedures | 2 | 2016 | 98 | 0.500 |
Why?
|
| Cyclohexanols | 1 | 2015 | 12 | 0.500 |
Why?
|
| Myasthenia Gravis | 1 | 2015 | 17 | 0.500 |
Why?
|
| Thyroid Hormones | 2 | 2015 | 31 | 0.500 |
Why?
|
| Reflex, Babinski | 1 | 2014 | 1 | 0.500 |
Why?
|
| Eyelashes | 1 | 2014 | 1 | 0.500 |
Why?
|
| Consciousness Monitors | 1 | 2014 | 2 | 0.500 |
Why?
|
| Hip Fractures | 1 | 2015 | 26 | 0.500 |
Why?
|
| Maxillofacial Prosthesis | 1 | 2014 | 3 | 0.500 |
Why?
|
| Drug Therapy, Combination | 6 | 2017 | 649 | 0.490 |
Why?
|
| Airway Obstruction | 1 | 2015 | 49 | 0.490 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2015 | 239 | 0.490 |
Why?
|
| Electromyography | 2 | 2012 | 184 | 0.480 |
Why?
|
| Artifacts | 1 | 2015 | 125 | 0.480 |
Why?
|
| Electroshock | 1 | 2014 | 36 | 0.480 |
Why?
|
| Patient Selection | 4 | 2017 | 592 | 0.480 |
Why?
|
| Heart Arrest | 3 | 2022 | 113 | 0.480 |
Why?
|
| Erythropoietin | 1 | 2015 | 96 | 0.470 |
Why?
|
| Metals | 1 | 2014 | 100 | 0.460 |
Why?
|
| Paralysis | 1 | 2013 | 35 | 0.450 |
Why?
|
| Dexmedetomidine | 1 | 2013 | 13 | 0.440 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 2013 | 57 | 0.440 |
Why?
|
| Literature, Modern | 1 | 2013 | 2 | 0.440 |
Why?
|
| Lupus Vasculitis, Central Nervous System | 1 | 2013 | 14 | 0.440 |
Why?
|
| Medicine in Literature | 1 | 2013 | 5 | 0.430 |
Why?
|
| Hemodynamics | 2 | 2013 | 705 | 0.430 |
Why?
|
| Injections, Intravenous | 2 | 2012 | 215 | 0.430 |
Why?
|
| Pregnancy Complications | 2 | 2012 | 286 | 0.430 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 6 | 2018 | 257 | 0.430 |
Why?
|
| Famous Persons | 1 | 2013 | 15 | 0.430 |
Why?
|
| Premedication | 3 | 2011 | 49 | 0.420 |
Why?
|
| Developmental Disabilities | 2 | 2013 | 119 | 0.420 |
Why?
|
| Vertebroplasty | 1 | 2012 | 16 | 0.420 |
Why?
|
| Intellectual Disability | 1 | 2013 | 114 | 0.420 |
Why?
|
| Lithium Carbonate | 4 | 2009 | 31 | 0.420 |
Why?
|
| Paresis | 1 | 2013 | 78 | 0.420 |
Why?
|
| Spinal Cord Compression | 1 | 2012 | 23 | 0.420 |
Why?
|
| Aggression | 2 | 2011 | 98 | 0.420 |
Why?
|
| Pulmonary Edema | 1 | 2012 | 37 | 0.410 |
Why?
|
| Aging | 2 | 2017 | 911 | 0.410 |
Why?
|
| Spinal Fractures | 1 | 2012 | 43 | 0.410 |
Why?
|
| Creatine Kinase | 1 | 2012 | 46 | 0.410 |
Why?
|
| Cannabis | 1 | 2013 | 115 | 0.410 |
Why?
|
| Diagnostic Errors | 1 | 2012 | 100 | 0.400 |
Why?
|
| Benzodiazepines | 2 | 2011 | 130 | 0.400 |
Why?
|
| Muscular Dystrophies | 1 | 2011 | 17 | 0.400 |
Why?
|
| Oligodendroglioma | 1 | 2011 | 18 | 0.400 |
Why?
|
| Memory Disorders | 2 | 2010 | 111 | 0.400 |
Why?
|
| Dopamine | 1 | 2014 | 474 | 0.390 |
Why?
|
| Remission Induction | 8 | 2016 | 111 | 0.390 |
Why?
|
| Troponin | 1 | 2011 | 25 | 0.390 |
Why?
|
| Defibrillators, Implantable | 1 | 2015 | 329 | 0.390 |
Why?
|
| Transcranial Magnetic Stimulation | 1 | 2016 | 413 | 0.390 |
Why?
|
| Neurilemmoma | 1 | 2011 | 26 | 0.380 |
Why?
|
| Vincristine | 1 | 2011 | 44 | 0.380 |
Why?
|
| Neurocognitive Disorders | 4 | 2019 | 23 | 0.380 |
Why?
|
| Cytarabine | 1 | 2011 | 44 | 0.380 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 33 | 0.380 |
Why?
|
| Tinnitus | 1 | 2011 | 22 | 0.370 |
Why?
|
| Self-Injurious Behavior | 1 | 2011 | 31 | 0.370 |
Why?
|
| Models, Biological | 1 | 2015 | 981 | 0.370 |
Why?
|
| Lewy Bodies | 1 | 2010 | 7 | 0.360 |
Why?
|
| Heart Diseases | 1 | 2013 | 276 | 0.360 |
Why?
|
| Biomarkers | 1 | 2016 | 1593 | 0.360 |
Why?
|
| Marijuana Abuse | 1 | 2013 | 251 | 0.360 |
Why?
|
| Risk Assessment | 5 | 2018 | 2007 | 0.360 |
Why?
|
| Status Epilepticus | 2 | 2009 | 74 | 0.350 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2010 | 99 | 0.350 |
Why?
|
| Autistic Disorder | 1 | 2011 | 77 | 0.350 |
Why?
|
| Bioprosthesis | 1 | 2010 | 101 | 0.340 |
Why?
|
| Psychoses, Substance-Induced | 3 | 2007 | 20 | 0.340 |
Why?
|
| Coronary Disease | 1 | 2011 | 358 | 0.340 |
Why?
|
| Double-Blind Method | 8 | 2017 | 1738 | 0.330 |
Why?
|
| Heart Valve Prosthesis | 1 | 2010 | 222 | 0.330 |
Why?
|
| Algorithms | 2 | 2008 | 1196 | 0.330 |
Why?
|
| Caffeine | 3 | 2013 | 81 | 0.330 |
Why?
|
| Pain | 1 | 2012 | 472 | 0.320 |
Why?
|
| Brain Diseases | 1 | 2009 | 78 | 0.320 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2019 | 1506 | 0.320 |
Why?
|
| Adolescent | 17 | 2020 | 8912 | 0.320 |
Why?
|
| Wounds and Injuries | 1 | 2011 | 334 | 0.300 |
Why?
|
| Brain Neoplasms | 1 | 2011 | 371 | 0.300 |
Why?
|
| Interferon-alpha | 1 | 2007 | 46 | 0.300 |
Why?
|
| Alzheimer Disease | 1 | 2012 | 565 | 0.290 |
Why?
|
| Patient-Centered Care | 1 | 2008 | 106 | 0.290 |
Why?
|
| Heart | 1 | 2012 | 850 | 0.290 |
Why?
|
| Aripiprazole | 3 | 2015 | 43 | 0.290 |
Why?
|
| Risperidone | 3 | 2015 | 48 | 0.290 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2006 | 22 | 0.280 |
Why?
|
| Surveys and Questionnaires | 3 | 2012 | 2800 | 0.280 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2013 | 756 | 0.270 |
Why?
|
| Hepatitis C, Chronic | 1 | 2007 | 86 | 0.270 |
Why?
|
| Myocardial Infarction | 2 | 2011 | 807 | 0.260 |
Why?
|
| Psychiatry | 2 | 2016 | 112 | 0.260 |
Why?
|
| Antiviral Agents | 1 | 2007 | 211 | 0.260 |
Why?
|
| Prognosis | 7 | 2012 | 2093 | 0.250 |
Why?
|
| Retreatment | 4 | 2008 | 59 | 0.250 |
Why?
|
| Child | 9 | 2020 | 6405 | 0.250 |
Why?
|
| Brain Injuries | 1 | 2008 | 268 | 0.240 |
Why?
|
| History, 20th Century | 4 | 2016 | 248 | 0.240 |
Why?
|
| Meningeal Neoplasms | 2 | 1998 | 42 | 0.240 |
Why?
|
| Meningioma | 2 | 1998 | 54 | 0.230 |
Why?
|
| United States | 7 | 2019 | 7367 | 0.230 |
Why?
|
| Psychotropic Drugs | 2 | 1997 | 83 | 0.230 |
Why?
|
| Practice Guidelines as Topic | 2 | 2017 | 772 | 0.230 |
Why?
|
| Hydrocortisone | 9 | 2000 | 291 | 0.220 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2011 | 2223 | 0.220 |
Why?
|
| Young Adult | 9 | 2020 | 5717 | 0.220 |
Why?
|
| Postoperative Complications | 2 | 2010 | 1615 | 0.220 |
Why?
|
| Bupropion | 2 | 1994 | 63 | 0.220 |
Why?
|
| Sumatriptan | 2 | 2001 | 4 | 0.210 |
Why?
|
| Medical Errors | 2 | 2014 | 80 | 0.210 |
Why?
|
| Retrospective Studies | 5 | 2018 | 7277 | 0.210 |
Why?
|
| Headache | 3 | 2001 | 68 | 0.210 |
Why?
|
| Reflex, Trigeminocardiac | 1 | 2022 | 1 | 0.210 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 2 | 2018 | 91 | 0.210 |
Why?
|
| Time Factors | 7 | 2011 | 4655 | 0.210 |
Why?
|
| Brain | 9 | 2012 | 2176 | 0.200 |
Why?
|
| Quality of Life | 3 | 2017 | 1515 | 0.200 |
Why?
|
| Publishing | 1 | 2003 | 89 | 0.200 |
Why?
|
| Clinical Competence | 1 | 2007 | 657 | 0.200 |
Why?
|
| Tomography, X-Ray Computed | 8 | 2013 | 2324 | 0.200 |
Why?
|
| Epilepsy, Tonic-Clonic | 2 | 2009 | 9 | 0.200 |
Why?
|
| Foot | 2 | 2012 | 66 | 0.190 |
Why?
|
| Risk Factors | 6 | 2020 | 5731 | 0.190 |
Why?
|
| Hypertension | 3 | 2017 | 1535 | 0.180 |
Why?
|
| Memory | 3 | 2011 | 214 | 0.180 |
Why?
|
| Bite Force | 1 | 2019 | 5 | 0.180 |
Why?
|
| Patient Care Planning | 1 | 2000 | 108 | 0.170 |
Why?
|
| Ambulatory Care | 2 | 2006 | 340 | 0.170 |
Why?
|
| Quality Assurance, Health Care | 2 | 1998 | 177 | 0.170 |
Why?
|
| Anesthesia, Dental | 1 | 2018 | 5 | 0.160 |
Why?
|
| Serotonin Receptor Agonists | 1 | 1998 | 34 | 0.160 |
Why?
|
| Follow-Up Studies | 6 | 2009 | 3259 | 0.160 |
Why?
|
| Clinical Trials as Topic | 6 | 2009 | 848 | 0.160 |
Why?
|
| Heart Rate | 2 | 2020 | 568 | 0.160 |
Why?
|
| Health Status | 3 | 2017 | 429 | 0.160 |
Why?
|
| Pregnancy | 3 | 2012 | 2334 | 0.160 |
Why?
|
| Neuromuscular Blockade | 1 | 2018 | 9 | 0.150 |
Why?
|
| Equipment Design | 1 | 2019 | 500 | 0.150 |
Why?
|
| Australia | 1 | 2019 | 235 | 0.150 |
Why?
|
| Affective Disorders, Psychotic | 2 | 1995 | 23 | 0.150 |
Why?
|
| Cerebellar Neoplasms | 1 | 1998 | 17 | 0.150 |
Why?
|
| Adrenergic Agonists | 1 | 2017 | 5 | 0.150 |
Why?
|
| Consensus | 1 | 2019 | 211 | 0.150 |
Why?
|
| Research Design | 5 | 2007 | 729 | 0.150 |
Why?
|
| Syncope | 1 | 2017 | 23 | 0.150 |
Why?
|
| Neuroleptic Malignant Syndrome | 1 | 1997 | 12 | 0.150 |
Why?
|
| Histamine Antagonists | 1 | 2017 | 22 | 0.150 |
Why?
|
| Epinephrine | 1 | 2017 | 103 | 0.150 |
Why?
|
| Neuromuscular Blocking Agents | 1 | 2017 | 4 | 0.150 |
Why?
|
| Patient Dropouts | 2 | 2009 | 98 | 0.150 |
Why?
|
| Certification | 1 | 1998 | 66 | 0.150 |
Why?
|
| Journalism | 1 | 2017 | 1 | 0.150 |
Why?
|
| Intracranial Aneurysm | 1 | 1998 | 87 | 0.150 |
Why?
|
| History, 21st Century | 3 | 2016 | 127 | 0.140 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 154 | 0.140 |
Why?
|
| Central Nervous System Agents | 1 | 2017 | 37 | 0.140 |
Why?
|
| Confusion | 1 | 2016 | 20 | 0.140 |
Why?
|
| Biological Variation, Population | 1 | 2016 | 8 | 0.140 |
Why?
|
| Time-to-Treatment | 1 | 2018 | 117 | 0.140 |
Why?
|
| Convulsive Therapy | 3 | 2014 | 3 | 0.140 |
Why?
|
| Patient Comfort | 1 | 2016 | 2 | 0.140 |
Why?
|
| Urticaria Pigmentosa | 1 | 2016 | 5 | 0.140 |
Why?
|
| Tachycardia | 2 | 2014 | 53 | 0.140 |
Why?
|
| Registries | 1 | 2020 | 733 | 0.140 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 2016 | 54 | 0.140 |
Why?
|
| Cardiovascular Diseases | 2 | 2013 | 940 | 0.140 |
Why?
|
| Monitoring, Physiologic | 2 | 2014 | 219 | 0.140 |
Why?
|
| Clinical Decision-Making | 1 | 2017 | 109 | 0.140 |
Why?
|
| Respiration, Artificial | 1 | 2017 | 190 | 0.130 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 1996 | 100 | 0.130 |
Why?
|
| Dose-Response Relationship, Radiation | 3 | 2008 | 84 | 0.130 |
Why?
|
| Long QT Syndrome | 1 | 2015 | 14 | 0.130 |
Why?
|
| Surgical Instruments | 1 | 2016 | 44 | 0.130 |
Why?
|
| GABA Modulators | 1 | 2015 | 26 | 0.130 |
Why?
|
| Safety | 2 | 2011 | 145 | 0.130 |
Why?
|
| Early Medical Intervention | 1 | 2015 | 16 | 0.130 |
Why?
|
| Child Development Disorders, Pervasive | 1 | 2015 | 26 | 0.130 |
Why?
|
| Facial Muscles | 1 | 2015 | 11 | 0.130 |
Why?
|
| Cerebral Angiography | 1 | 2016 | 151 | 0.130 |
Why?
|
| Airway Management | 1 | 2015 | 20 | 0.130 |
Why?
|
| Pneumonia, Aspiration | 1 | 2015 | 22 | 0.130 |
Why?
|
| Face | 1 | 2015 | 46 | 0.130 |
Why?
|
| Public Opinion | 2 | 1995 | 32 | 0.130 |
Why?
|
| Informed Consent | 2 | 2012 | 127 | 0.130 |
Why?
|
| Patient Care Team | 1 | 2017 | 311 | 0.120 |
Why?
|
| Motor Neuron Disease | 1 | 2014 | 10 | 0.120 |
Why?
|
| Foreign Bodies | 1 | 2015 | 58 | 0.120 |
Why?
|
| Hypothyroidism | 1 | 2014 | 24 | 0.120 |
Why?
|
| Decision Making | 1 | 2018 | 410 | 0.120 |
Why?
|
| Diagnosis, Differential | 4 | 2015 | 1140 | 0.120 |
Why?
|
| Tachycardia, Supraventricular | 1 | 1994 | 73 | 0.120 |
Why?
|
| Frontal Lobe | 3 | 2011 | 156 | 0.120 |
Why?
|
| Osteoporosis | 1 | 2015 | 88 | 0.120 |
Why?
|
| Designer Drugs | 1 | 2013 | 7 | 0.120 |
Why?
|
| Interprofessional Relations | 1 | 2015 | 188 | 0.120 |
Why?
|
| Radiography | 1 | 2015 | 572 | 0.110 |
Why?
|
| Health Care Reform | 1 | 1994 | 62 | 0.110 |
Why?
|
| Comorbidity | 2 | 2017 | 1426 | 0.110 |
Why?
|
| Bundle-Branch Block | 1 | 2014 | 50 | 0.110 |
Why?
|
| Neurologic Examination | 1 | 2013 | 107 | 0.110 |
Why?
|
| Poetry as Topic | 1 | 2013 | 4 | 0.110 |
Why?
|
| Hallucinations | 2 | 1992 | 19 | 0.110 |
Why?
|
| Cognitive Dysfunction | 1 | 2016 | 176 | 0.110 |
Why?
|
| Imipramine | 4 | 1994 | 44 | 0.110 |
Why?
|
| Indicator Dilution Techniques | 1 | 2012 | 8 | 0.110 |
Why?
|
| Neuromuscular Nondepolarizing Agents | 1 | 2012 | 11 | 0.110 |
Why?
|
| Reproducibility of Results | 2 | 2012 | 2077 | 0.100 |
Why?
|
| Cerebral Ventricles | 3 | 1988 | 36 | 0.100 |
Why?
|
| Leukocytosis | 1 | 2012 | 13 | 0.100 |
Why?
|
| Blood Pressure | 4 | 2012 | 1451 | 0.100 |
Why?
|
| Internship and Residency | 1 | 1998 | 596 | 0.100 |
Why?
|
| Temporal Lobe | 2 | 2011 | 125 | 0.100 |
Why?
|
| Equipment Failure | 1 | 2012 | 112 | 0.100 |
Why?
|
| Tranylcypromine | 1 | 1991 | 8 | 0.100 |
Why?
|
| Intelligence Tests | 1 | 2011 | 32 | 0.100 |
Why?
|
| Multiple Sclerosis | 3 | 1994 | 132 | 0.100 |
Why?
|
| Midazolam | 1 | 2011 | 46 | 0.100 |
Why?
|
| Periodicals as Topic | 1 | 2014 | 158 | 0.100 |
Why?
|
| Age Factors | 5 | 2014 | 1864 | 0.100 |
Why?
|
| Television | 1 | 1991 | 28 | 0.100 |
Why?
|
| Central Nervous System Stimulants | 1 | 2013 | 221 | 0.100 |
Why?
|
| Affect | 2 | 2011 | 218 | 0.090 |
Why?
|
| Dogs | 1 | 1992 | 490 | 0.090 |
Why?
|
| Prolactin | 6 | 1999 | 61 | 0.090 |
Why?
|
| Delirium | 1 | 2011 | 45 | 0.090 |
Why?
|
| Gastroesophageal Reflux | 1 | 2013 | 318 | 0.090 |
Why?
|
| Movement | 1 | 2012 | 179 | 0.090 |
Why?
|
| Smell | 1 | 1992 | 131 | 0.090 |
Why?
|
| Rituximab | 1 | 2011 | 61 | 0.090 |
Why?
|
| Muscle Contraction | 1 | 2011 | 210 | 0.090 |
Why?
|
| Fluvoxamine | 4 | 1994 | 22 | 0.090 |
Why?
|
| Executive Function | 1 | 2011 | 106 | 0.090 |
Why?
|
| Patient Satisfaction | 1 | 2013 | 378 | 0.090 |
Why?
|
| Language | 1 | 2011 | 120 | 0.090 |
Why?
|
| Esophageal Diseases | 1 | 1990 | 95 | 0.090 |
Why?
|
| Mental Status Schedule | 1 | 2010 | 31 | 0.090 |
Why?
|
| Breast Feeding | 1 | 2012 | 159 | 0.090 |
Why?
|
| Limbic System | 2 | 1987 | 106 | 0.090 |
Why?
|
| Reoperation | 2 | 2010 | 467 | 0.090 |
Why?
|
| Procaine | 3 | 1994 | 9 | 0.090 |
Why?
|
| Orgasm | 1 | 2009 | 3 | 0.090 |
Why?
|
| Citalopram | 1 | 2009 | 30 | 0.090 |
Why?
|
| Chi-Square Distribution | 2 | 2008 | 546 | 0.090 |
Why?
|
| Sexual Dysfunctions, Psychological | 1 | 2009 | 17 | 0.090 |
Why?
|
| Personality Inventory | 2 | 2009 | 197 | 0.080 |
Why?
|
| Psychometrics | 2 | 2009 | 514 | 0.080 |
Why?
|
| Regression Analysis | 2 | 2010 | 737 | 0.080 |
Why?
|
| Behavior | 1 | 2009 | 59 | 0.080 |
Why?
|
| Calcinosis | 1 | 1991 | 241 | 0.080 |
Why?
|
| Behavior, Animal | 1 | 1992 | 470 | 0.080 |
Why?
|
| Personality | 1 | 2009 | 66 | 0.080 |
Why?
|
| Health Services Accessibility | 1 | 2013 | 581 | 0.080 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2010 | 164 | 0.080 |
Why?
|
| Family | 1 | 2010 | 293 | 0.080 |
Why?
|
| Anxiety Disorders | 1 | 2011 | 426 | 0.080 |
Why?
|
| Heart Transplantation | 1 | 1991 | 328 | 0.080 |
Why?
|
| Unnecessary Procedures | 1 | 2008 | 49 | 0.080 |
Why?
|
| Patient Readmission | 2 | 2021 | 267 | 0.080 |
Why?
|
| Sensitivity and Specificity | 1 | 2012 | 1753 | 0.080 |
Why?
|
| Data Interpretation, Statistical | 1 | 2009 | 329 | 0.080 |
Why?
|
| Sleep Deprivation | 1 | 1988 | 81 | 0.070 |
Why?
|
| Long-Term Care | 1 | 2007 | 53 | 0.070 |
Why?
|
| Borderline Personality Disorder | 1 | 1987 | 13 | 0.070 |
Why?
|
| Statistics, Nonparametric | 1 | 2008 | 306 | 0.070 |
Why?
|
| Interview, Psychological | 1 | 2007 | 113 | 0.070 |
Why?
|
| Personality Disorders | 1 | 1987 | 44 | 0.070 |
Why?
|
| Treatment Failure | 1 | 2007 | 216 | 0.070 |
Why?
|
| Observer Variation | 1 | 2008 | 330 | 0.070 |
Why?
|
| Agoraphobia | 1 | 1987 | 59 | 0.070 |
Why?
|
| Antidepressive Agents, Tricyclic | 2 | 2009 | 45 | 0.070 |
Why?
|
| Tourette Syndrome | 1 | 2006 | 8 | 0.070 |
Why?
|
| Drug Synergism | 1 | 2007 | 260 | 0.070 |
Why?
|
| Panic | 1 | 1987 | 97 | 0.070 |
Why?
|
| Bias | 1 | 2007 | 148 | 0.070 |
Why?
|
| Motor Cortex | 1 | 2008 | 158 | 0.070 |
Why?
|
| Polyethylene Glycols | 1 | 2007 | 149 | 0.070 |
Why?
|
| United Kingdom | 1 | 2007 | 152 | 0.070 |
Why?
|
| Adenoma, Chromophobe | 1 | 1985 | 1 | 0.070 |
Why?
|
| Bromocriptine | 1 | 1985 | 8 | 0.070 |
Why?
|
| Fluphenazine | 1 | 1985 | 19 | 0.070 |
Why?
|
| Education, Medical, Continuing | 1 | 2007 | 136 | 0.070 |
Why?
|
| Phobic Disorders | 1 | 1987 | 227 | 0.070 |
Why?
|
| Recombinant Proteins | 1 | 2007 | 742 | 0.070 |
Why?
|
| Fear | 1 | 1987 | 239 | 0.060 |
Why?
|
| Blindness | 1 | 2005 | 22 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2008 | 1342 | 0.060 |
Why?
|
| Pituitary Neoplasms | 1 | 1985 | 52 | 0.060 |
Why?
|
| Adrenocorticotropic Hormone | 5 | 1994 | 106 | 0.060 |
Why?
|
| Anticonvulsants | 2 | 2005 | 223 | 0.060 |
Why?
|
| Longitudinal Studies | 1 | 2008 | 1054 | 0.060 |
Why?
|
| Education, Medical, Graduate | 1 | 2007 | 214 | 0.060 |
Why?
|
| Somatoform Disorders | 1 | 2004 | 35 | 0.060 |
Why?
|
| Patients | 1 | 1985 | 69 | 0.060 |
Why?
|
| Electrodes, Implanted | 1 | 2005 | 98 | 0.060 |
Why?
|
| Proportional Hazards Models | 1 | 2006 | 792 | 0.060 |
Why?
|
| Corticotropin-Releasing Hormone | 3 | 1994 | 79 | 0.060 |
Why?
|
| Cerebral Cortex | 2 | 1997 | 415 | 0.060 |
Why?
|
| Pteridines | 1 | 1983 | 5 | 0.060 |
Why?
|
| Biopterin | 1 | 1983 | 10 | 0.060 |
Why?
|
| Inpatients | 1 | 1985 | 208 | 0.060 |
Why?
|
| Torture | 1 | 1983 | 1 | 0.060 |
Why?
|
| Antineoplastic Agents | 1 | 2011 | 1070 | 0.060 |
Why?
|
| Meta-Analysis as Topic | 1 | 2003 | 57 | 0.060 |
Why?
|
| Drug Industry | 1 | 2003 | 54 | 0.050 |
Why?
|
| Trigeminal Nerve | 1 | 2022 | 22 | 0.050 |
Why?
|
| Memantine | 1 | 2022 | 10 | 0.050 |
Why?
|
| Triiodothyronine | 1 | 2022 | 22 | 0.050 |
Why?
|
| Attitude of Health Personnel | 2 | 2016 | 442 | 0.050 |
Why?
|
| Substance-Related Disorders | 1 | 1991 | 1242 | 0.050 |
Why?
|
| Lithium Chloride | 1 | 2001 | 10 | 0.050 |
Why?
|
| Antimanic Agents | 1 | 2001 | 21 | 0.050 |
Why?
|
| Endpoint Determination | 1 | 2002 | 82 | 0.050 |
Why?
|
| Anxiety | 1 | 2004 | 422 | 0.050 |
Why?
|
| Vasoconstrictor Agents | 1 | 2001 | 107 | 0.050 |
Why?
|
| Animals | 5 | 2014 | 20881 | 0.050 |
Why?
|
| Incidence | 1 | 2005 | 1603 | 0.050 |
Why?
|
| Denmark | 1 | 2020 | 24 | 0.040 |
Why?
|
| Protective Factors | 1 | 2020 | 24 | 0.040 |
Why?
|
| Dexamethasone | 1 | 2000 | 150 | 0.040 |
Why?
|
| Equivalence Trials as Topic | 1 | 2018 | 7 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 116 | 0.040 |
Why?
|
| Glucocorticoids | 1 | 2000 | 222 | 0.040 |
Why?
|
| Epilepsy, Generalized | 1 | 1997 | 15 | 0.040 |
Why?
|
| Tachycardia, Paroxysmal | 1 | 1997 | 4 | 0.040 |
Why?
|
| Administration, Oral | 1 | 1998 | 411 | 0.040 |
Why?
|
| Heart Aneurysm | 1 | 1997 | 21 | 0.040 |
Why?
|
| Haloperidol | 1 | 1997 | 95 | 0.040 |
Why?
|
| Huntington Disease | 1 | 1997 | 15 | 0.040 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 143 | 0.040 |
Why?
|
| Cerebellum | 1 | 1998 | 103 | 0.040 |
Why?
|
| Schizophrenia, Catatonic | 1 | 2016 | 1 | 0.040 |
Why?
|
| Evoked Potentials | 1 | 1997 | 61 | 0.040 |
Why?
|
| Pandemics | 1 | 2020 | 352 | 0.030 |
Why?
|
| Anti-Anxiety Agents | 1 | 1997 | 107 | 0.030 |
Why?
|
| Research | 1 | 1996 | 214 | 0.030 |
Why?
|
| Labetalol | 1 | 2014 | 10 | 0.030 |
Why?
|
| Parasympatholytics | 1 | 1994 | 19 | 0.030 |
Why?
|
| Thyroid Gland | 1 | 1994 | 67 | 0.030 |
Why?
|
| Electric Stimulation | 1 | 1995 | 218 | 0.030 |
Why?
|
| Trephining | 1 | 1994 | 1 | 0.030 |
Why?
|
| Isotonic Solutions | 1 | 1994 | 25 | 0.030 |
Why?
|
| Growth Hormone | 3 | 1994 | 51 | 0.030 |
Why?
|
| Hematoma, Subdural | 1 | 1994 | 19 | 0.030 |
Why?
|
| Cardiotonic Agents | 1 | 1994 | 71 | 0.030 |
Why?
|
| Curriculum | 1 | 1998 | 575 | 0.030 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2014 | 189 | 0.030 |
Why?
|
| Acute Disease | 1 | 1995 | 658 | 0.030 |
Why?
|
| Hypothalamus | 1 | 1994 | 78 | 0.030 |
Why?
|
| Students, Medical | 1 | 2016 | 210 | 0.030 |
Why?
|
| Panic Disorder | 1 | 1994 | 121 | 0.030 |
Why?
|
| Anesthetics, Local | 1 | 1994 | 83 | 0.030 |
Why?
|
| Receptors, Cholinergic | 1 | 1993 | 30 | 0.030 |
Why?
|
| Catecholamines | 1 | 1993 | 73 | 0.030 |
Why?
|
| Myocardial Ischemia | 1 | 1994 | 172 | 0.030 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 1994 | 154 | 0.030 |
Why?
|
| Cardiovascular System | 1 | 1993 | 85 | 0.030 |
Why?
|
| Public Relations | 1 | 1991 | 2 | 0.020 |
Why?
|
| Hand | 1 | 1992 | 90 | 0.020 |
Why?
|
| Rupture, Spontaneous | 1 | 1990 | 21 | 0.020 |
Why?
|
| Antihypertensive Agents | 1 | 1995 | 498 | 0.020 |
Why?
|
| Patient Compliance | 2 | 2001 | 402 | 0.020 |
Why?
|
| Corpus Callosum | 1 | 1991 | 29 | 0.020 |
Why?
|
| Caudate Nucleus | 1 | 1991 | 56 | 0.020 |
Why?
|
| Brain Mapping | 2 | 1991 | 532 | 0.020 |
Why?
|
| Esophagoscopy | 1 | 1990 | 72 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2014 | 506 | 0.020 |
Why?
|
| Gyrus Cinguli | 1 | 1991 | 113 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2014 | 931 | 0.020 |
Why?
|
| Calibration | 1 | 2009 | 73 | 0.020 |
Why?
|
| Paroxetine | 1 | 2009 | 28 | 0.020 |
Why?
|
| Cushing Syndrome | 2 | 1986 | 7 | 0.020 |
Why?
|
| Septum Pellucidum | 1 | 1989 | 7 | 0.020 |
Why?
|
| Oximes | 1 | 1989 | 10 | 0.020 |
Why?
|
| Schizophrenic Psychology | 1 | 1989 | 53 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2009 | 1745 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2014 | 2358 | 0.020 |
Why?
|
| Endocrine Glands | 1 | 1987 | 7 | 0.020 |
Why?
|
| Perceptual Distortion | 1 | 1987 | 4 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 2009 | 295 | 0.020 |
Why?
|
| Cerebral Ventriculography | 1 | 1986 | 4 | 0.020 |
Why?
|
| Neoplasms | 1 | 1997 | 1667 | 0.020 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2009 | 435 | 0.020 |
Why?
|
| Hospitals, Municipal | 1 | 1985 | 2 | 0.020 |
Why?
|
| Hospitals, General | 1 | 1985 | 12 | 0.020 |
Why?
|
| Drug Interactions | 1 | 1985 | 289 | 0.020 |
Why?
|
| Hospitals, University | 1 | 1985 | 169 | 0.020 |
Why?
|
| Drug Tolerance | 1 | 1985 | 80 | 0.020 |
Why?
|
| Hospitals, Veterans | 1 | 1985 | 147 | 0.020 |
Why?
|
| Platelet Count | 1 | 1984 | 100 | 0.020 |
Why?
|
| Pulse | 2 | 1994 | 23 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2007 | 1465 | 0.010 |
Why?
|
| Polychondritis, Relapsing | 1 | 1983 | 3 | 0.010 |
Why?
|
| Blood Platelets | 1 | 1984 | 284 | 0.010 |
Why?
|
| Mental Health Services | 1 | 1985 | 199 | 0.010 |
Why?
|
| Atrophy | 1 | 1983 | 112 | 0.010 |
Why?
|
| Referral and Consultation | 1 | 1985 | 383 | 0.010 |
Why?
|
| Analysis of Variance | 2 | 1994 | 1040 | 0.010 |
Why?
|
| Administration, Intranasal | 1 | 2001 | 88 | 0.010 |
Why?
|
| Preanesthetic Medication | 1 | 2000 | 6 | 0.010 |
Why?
|
| Temporal Bone | 1 | 1999 | 53 | 0.010 |
Why?
|
| Dominance, Cerebral | 1 | 1999 | 65 | 0.010 |
Why?
|
| Administration, Sublingual | 1 | 1997 | 15 | 0.010 |
Why?
|
| Nitroglycerin | 1 | 1997 | 20 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2004 | 3705 | 0.010 |
Why?
|
| Bone Neoplasms | 1 | 1997 | 100 | 0.010 |
Why?
|
| Carcinoma, Renal Cell | 1 | 1997 | 110 | 0.010 |
Why?
|
| Chronic Disease | 2 | 1994 | 1330 | 0.010 |
Why?
|
| Stress, Psychological | 1 | 1983 | 824 | 0.010 |
Why?
|
| Kidney Neoplasms | 1 | 1997 | 206 | 0.010 |
Why?
|
| Hippocampus | 1 | 1999 | 471 | 0.010 |
Why?
|
| Psychosurgery | 1 | 1995 | 9 | 0.010 |
Why?
|
| Ventricular Function, Left | 1 | 1997 | 481 | 0.010 |
Why?
|
| Lactates | 1 | 1994 | 29 | 0.010 |
Why?
|
| Sensation | 1 | 1994 | 49 | 0.010 |
Why?
|
| Organ Culture Techniques | 1 | 1994 | 122 | 0.010 |
Why?
|
| Sodium Chloride | 1 | 1994 | 136 | 0.010 |
Why?
|
| Hypotension, Orthostatic | 1 | 1993 | 15 | 0.010 |
Why?
|
| Normetanephrine | 1 | 1993 | 8 | 0.010 |
Why?
|
| Vanilmandelic Acid | 1 | 1993 | 6 | 0.010 |
Why?
|
| Metanephrine | 1 | 1993 | 11 | 0.010 |
Why?
|
| Methoxyhydroxyphenylglycol | 1 | 1993 | 41 | 0.010 |
Why?
|
| Receptors, Adrenergic | 1 | 1993 | 68 | 0.010 |
Why?
|
| Lactic Acid | 1 | 1994 | 86 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 1994 | 334 | 0.010 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 1993 | 40 | 0.010 |
Why?
|
| Placebos | 1 | 1993 | 195 | 0.010 |
Why?
|
| Reference Values | 1 | 1994 | 579 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 1994 | 567 | 0.010 |
Why?
|
| Norepinephrine | 1 | 1993 | 276 | 0.010 |
Why?
|
| Sex Factors | 1 | 1994 | 1266 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1994 | 2083 | 0.010 |
Why?
|
| Outpatients | 1 | 1989 | 127 | 0.000 |
Why?
|
| Random Allocation | 1 | 1989 | 442 | 0.000 |
Why?
|
| Infant | 1 | 1994 | 2891 | 0.000 |
Why?
|
| Child, Preschool | 1 | 1994 | 3187 | 0.000 |
Why?
|
| Stimulation, Chemical | 1 | 1986 | 57 | 0.000 |
Why?
|
| Pituitary Gland | 1 | 1986 | 29 | 0.000 |
Why?
|
| Rats | 1 | 1994 | 5300 | 0.000 |
Why?
|
| Macaca fascicularis | 1 | 1984 | 31 | 0.000 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 1984 | 150 | 0.000 |
Why?
|
| Pituitary-Adrenal System | 1 | 1984 | 138 | 0.000 |
Why?
|
| Epilepsy | 1 | 1987 | 336 | 0.000 |
Why?
|
| Kinetics | 1 | 1984 | 1047 | 0.000 |
Why?
|
| Adrenal Cortex Hormones | 1 | 1983 | 186 | 0.000 |
Why?
|